Mavenclad Works Best at Reducing Relapses & Managing Fatigue Through Medication episode artwork

EPISODE · Mar 11, 2022 · 11 MIN

Mavenclad Works Best at Reducing Relapses & Managing Fatigue Through Medication

from MS News & Perspectives · host MS News Today

Multiple Sclerosis News Today’s multimedia associate, Price Wooldridge, covers how MS patients on Mavenclad are less likely to experience a disease relapse than those on other oral DMTs like Gilenya, Tecfidera, or Aubagio.He also reads “The Double-Edged Sword of Fatigue Medications”, from Beth Ullah's column "Through the Looking Glass".=================================== Are you interested in learning more about multiple sclerosis? If so, please visit:https://multiplesclerosisnewstoday.com/ =====================================To join in on conversations regarding multiple sclerosis, please visit:https://multiplesclerosisnewstoday.com/forums/

Episode metadata supplied by the publisher feed · Published Mar 11, 2022

Embed this episode

NOW PLAYING

Mavenclad Works Best at Reducing Relapses & Managing Fatigue Through Medication

0:00 11:59

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

No similar episodes found.

No similar podcasts found.

Frequently Asked Questions

How long is this episode of MS News & Perspectives?

This episode is 11 minutes long.

When was this MS News & Perspectives episode published?

This episode was published on March 11, 2022.

Can I download this MS News & Perspectives episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.
URL copied to clipboard!